Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin versus placebo for treatment-resistant depression feasibility study
2018-003573-97Phase 2Unknown
- Sponsor
- King's College London
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in major depressive disorder (MDD) comparing Psilocybin 25 mg with Placebo (2 arms). Primary endpoint: Feasibility metrics. Status: unknown.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-003573-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003573-97.